Identification of Two Subsets of Murine DC1 Dendritic Cells That Differ by Surface Phenotype, Gene Expression, and Function

Classical dendritic cells (cDCs) in mice have been divided into 2 major subsets based on the expression of nuclear transcription factors: a CD8 + Irf8 + Batf3 dependent (DC1) subset, and a CD8 - Irf4 + (DC2) subset. We found that the CD8 + DC1 subset can be further divided into CD8 + DC1a and CD8 +...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 746469
Main Authors Hongo, David, Zheng, Pingping, Dutt, Suparna, Pawar, Rahul D., Meyer, Everett, Engleman, Edgar G., Strober, Samuel
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 26.10.2021
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2021.746469

Cover

More Information
Summary:Classical dendritic cells (cDCs) in mice have been divided into 2 major subsets based on the expression of nuclear transcription factors: a CD8 + Irf8 + Batf3 dependent (DC1) subset, and a CD8 - Irf4 + (DC2) subset. We found that the CD8 + DC1 subset can be further divided into CD8 + DC1a and CD8 + DC1b subsets by differences in surface receptors, gene expression, and function. Whereas all 3 DC subsets can act alone to induce potent Th1 cytokine responses to class I and II MHC restricted peptides derived from ovalbumin (OVA) by OT-I and OT-II transgenic T cells, only the DC1b subset could effectively present glycolipid antigens to natural killer T (NKT) cells. Vaccination with OVA protein pulsed DC1b and DC2 cells were more effective in reducing the growth of the B16-OVA melanoma as compared to pulsed DC1a cells in wild type mice. In conclusion, the Batf3-/- dependent DC1 cells can be further divided into two subsets with different immune functional profiles in vitro and in vivo .
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Antigen Presenting Cell Biology, a section of the journal Frontiers in Immunology
Edited by: Daniel Saban, Duke University, United States
Reviewed by: Luc Van Kaer, Vanderbilt University, United States; Joana Dias, Vaccine Research Center (NIAID), United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.746469